Core Viewpoint - The stock of Basestone Pharmaceuticals (02616) has seen a significant increase, with a rise of over 9%, currently trading at 10.35 HKD, with a transaction volume of 201 million HKD. This surge follows the announcement of a substantial share acquisition by the Government of Singapore Investment Corporation (GIC) [1] Group 1: Share Acquisition - On August 18, GIC Private Limited increased its stake in Basestone Pharmaceuticals by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD. This acquisition raised GIC's ownership from 0.00% to 5.49% [1] Group 2: Clinical Trials and Product Pipeline - Guotou Securities reported that Basestone's core product, the second-generation IO product CS2009, is currently undergoing global multi-center Phase I/II clinical trials in Australia and China, with plans to expand to the U.S. for Phase II enrollment. The company expects to exceed 100 patients by the end of the year [1] - The company plans to present data from the Phase I clinical study, including safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity, at the ESMO conference in October 2025, which is highly anticipated [1] - Given the potential for product volume growth and a rich clinical development pipeline, the future development prospects for the company appear promising [1]

Core Viewpoint - The stock of Basilea Pharmaceutica (02616) has seen a significant increase, with a rise of over 9% and a current price of 10.35 HKD, driven by recent investment activities and positive clinical trial developments [1] Group 1: Investment Activity - Singapore's Government Investment Corporation (GIC Private Limited) has increased its stake in Basilea Pharmaceutica by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD [1] - Following this acquisition, GIC's ownership in Basilea has risen from 0.00% to 5.49% [1] Group 2: Clinical Development - Basilea's core product, the second-generation IO product CS2009, is currently undergoing global multi-center Phase I/II clinical trials in Australia and China, with plans to expand to the U.S. for Phase II enrollment [1] - The company anticipates that the number of patients enrolled will exceed 100 by the end of the year, with plans to initiate Phase Ib/II dose expansion and registration studies in the second half of 2025 [1] - Data from the Phase I clinical study, including safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity, is expected to be presented at the ESMO conference in October 2025, generating significant interest [1] Group 3: Future Outlook - Given the potential for product launches and a robust clinical development pipeline, the future growth prospects for Basilea are considered promising [1]